SAN ANTONIO — New results from a landmark women's health study raise the
exciting possibility that bone-building drugs such as Fosamax and Actonel may
help prevent breast cancer.
Women who already were using these medicines when the study began were about
one-third less likely to develop invasive breast cancer over the next seven
years than women not taking such pills, doctors reported Thursday.
The study is not enough to prove that these drugs, called bisphosphonates,
prevent cancer. More definitive studies should give a clearer answer in a year
or two.
Yet it greatly amplifies the hopeful buzz that started last year when
researchers reported that a bisphosphonate cut the chances that cancer would
come back in women already treated for the disease.
"Now we're actually looking at this in the general population — healthy women
who have never had breast cancer. And it looks like it's protective in those
women as well," said Dr. Peter Ravdin of the University of Texas Health Science
Center at San Antonio.
"There's a strengthening story here," said Ravdin, who helped review the
research for the San Antonio Breast Cancer Symposium, where results were
reported Thursday. "This is very promising."
Millions of women already take bisphosphonates for bone-thinning osteoporosis,
or to prevent fractures from cancer that has spread to their bones.
The drugs range in cost from $100 for a three-month supply of the generic
version of Merck & Co. Inc.'s Fosamax pills to as much as $1,200 for an infusion
of Novartis AG's Zometa, given every six months for osteoporosis. Other brands
are e GlaxoSmithKline PLC's Boniva and Warner Chilcott PLC's Actonel.
After last year's surprise finding that Zometa cut the risk of cancer
recurrence, doctors wondered: Is it just making bones more resistant to cancer's
spread, or does it have wider anti-tumor effects that may prevent cancer from
developing in the first place?
Dr. Rowan Chlebowski of Los Angeles Biomedical Research Institute at Harbor-UCLA
Medical Center in Torrance, Calif., sought answers from the Women's Health
Initiative, a federally funded study best known for revealing previously
unrecognized risks from estrogen and progestin pills after menopause.
Of the 151,592 participants, 2,216 were taking bisphosphonates — mostly Fosamax
— when the study began. About seven years later, 31 percent fewer invasive
breast cancer cases had occurred among those women than the others. The benefit
persisted even after researchers took into account differences in age, smoking,
weight, hormone and vitamin D use, and other things that affect bone density and
breast cancer risk.
However, women taking bisphosphonates were more likely to develop a noninvasive
tumor of the milk duct called DCIS. Chlebowski contends this is an acceptable
trade-off: For every 1,000 women taking a bisphosphonate for one year, one fewer
case of invasive, life-threatening breast cancer would occur.
Overall, the results suggest that bisphosphonates have direct anti-cancer
effects and are not just helping bones resist cancer's spread.
"If it only worked in the bone marrow then you wouldn't be influencing
incidence" of new cancers, said Chlebowski, who has consulted for makers of
bisphosphonates and other cancer prevention drugs.
A second study supported that view. Dr. Gad Rennert of the Technion-Israel
Institute of Technology in Haifa, Israel, compared about 2,000 postmenopausal
women with breast cancer to 2,000 similar women without the disease. Those with
cancer were 29 percent less likely to have been taking bisphosphonates, he
found.
Neither study collected information on side effects. Bisphosphonates can cause
bone, joint or muscle pain and in rare cases, jawbone decay.
"These are drugs that, generally speaking, are relatively well tolerated" and
fairly safe, but they still should not be taken for cancer prevention until more
definitive studies show their risks and benefits, said Dr. Eric Winer of the
Dana-Farber Cancer Center in Boston. He has no financial ties to any makers of
these drugs.
The only drugs approved now for preventing breast cancer in healthy women at
higher risk are the hormone blockers tamoxifen and raloxifene. Side effects such
as hot flashes, high blood pressure and a higher risk of blood clots have
limited their use.
The cancer conference is sponsored by the American Association for Cancer
Research, Baylor College of Medicine and the UT Health Science Center.
Source : The Associated Press
